About Genomenon
Genomenon is a company based in Ann Arbor (United States) founded in 2014. Genomenon has raised $42.87 million across 14 funding rounds from investors including NIH, University of Michigan and HHS. Genomenon has completed 1 acquisition, including Boston Genetics. Genomenon offers products and services including Mastermind, Cancer Knowledgebase, and Curation Services. Genomenon operates in a competitive market with competitors including Human Longevity, Denali Therapeutics, DNAnexus, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter Ann Arbor, United States
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genomenon, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$42.87 M (USD)
in 14 rounds
-
Latest Funding Round
$6.03 M (USD), Series C
Jul 15, 2026
-
Investors
NIH
& 18 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genomenon
Genomenon offers a comprehensive portfolio of products and services, including Mastermind, Cancer Knowledgebase, and Curation Services.
AI tool for analyzing and interpreting genomic datasets.
Platform connecting cancer variants to therapies and trials.
Expert services for variant classification and analysis.
People of Genomenon
Unlock access to complete
Unlock access to complete
Funding Insights of Genomenon
Genomenon has successfully raised a total of $42.87M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $6.03 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genomenon
Genomenon has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, University of Michigan and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in growth-stage startups by Beringea.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in medical startups.
|
Locked | Locked | Locked |
Investor details for Genomenon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomenon
Genomenon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Boston Genetics.
Investment portfolio details for Genomenon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapy-based drug development services are provided.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Genomenon
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Genomenon
Detailed financials for Genomenon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomenon Comparisons
Peer comparison for Genomenon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genomenon
Genomenon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Human Longevity, Denali Therapeutics, DNAnexus, Poseida Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomics data and cell therapy-based diagnostic and therapeutic solutions
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Detailed competitors of Genomenon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomenon
Complete news archive for Genomenon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomenon
Genomenon was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Genomenon is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Genomenon is a funded company, having raised a total of $42.87M across 14 funding rounds to date.
Genomenon was founded in 2014 in Ann Arbor, United States, within the bioinformatics sector. AI-driven tools and a comprehensive meta-database of genomic variants are provided for genomic analysis. MASTERMIND organizes variants into clinical categories based on disease associations determined by automated algorithms. SAVANT identifies actionable genetic variants from gene panels, exomes, or patient genomes. PRODIGY analyzes multi-sample datasets to pinpoint disease-causing variants for research purposes.
Genomenon's top competitors include DNAnexus, Juno Therapeutics and Human Longevity.
Genomenon offers Mastermind, Cancer Knowledgebase, and Curation Services.
Genomenon has made 1 acquisition, including Boston Genetics.
Genomenon has 19 investors. Key investors include NIH, University of Michigan, HHS, Broadoak Capital Partners, and IrishAngels.